Chemotherapy with or without pembrolizumab followed by maintenance with olaparib or placebo for first-line treatment of advanced BRCA nonmutated epithelial ovarian cancer: Results from the randomized phase III ENGOT-OV43/GOG-3036/KEYLYNK-001 study
作者
Matthew A. Powell,David Cibula,Els Van Nieuwenhuysen,Keiichi Fujiwara,Matthew J. Oliver,Jung-Yun Lee,Giovanni Scambia,Jacob Korach,Nicoletta Colombo,Radosław Mądry,Karin Yamada,John R. Moroney,Ignace Vergote